Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

计划入组 107 人 · 首次发布于 2008 年 3 月 17 日

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

计划入组 46 人 · 首次发布于 2012 年 2 月 10 日

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

计划入组 81 人 · 首次发布于 2014 年 12 月 30 日

CRaf (Plexium)

CRAF Degrader therapy(Plexium)

selective monovalent direct degrader(CRAF, RAS-driven cancer)

CANADIAN CRAFT CANNABIS COMPANY PTY LTD

Australia

JOANN Inc.

United States

Lazard

Servier and Black Diamond Therapeutics Forge $780M Global Licensing Deal for Novel RAF/RAS Cancer Therapy

Verastem Oncology Completes FDA Submission for Avutometinib Plus Defactinib in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Refinances Debt and Advances Avutometinib/Defactinib Combination